[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623810":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":50,"centralContacts":54,"locations":60,"responsibleParty":95,"collaborators":46,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":46,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":46,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":46,"overallStatus":63,"whyStopped":46,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Shanghai Argo Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14,18,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"BW-50218 Dose 1","EXPERIMENTAL","Single dose of BW-50218 injection (Dose 1).",[13],"Drug: BW-50218 Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"BW-50218 Dose 2","Single dose of BW-50218 injection (Dose 2).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"BW-50218 Dose 3","Single dose of BW-50218 injection (Dose 3).",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"BW-50218 Dose 4","Single dose of BW-50218 injection (Dose 4).",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"BW-50218 Dose 5","Single dose of BW-50218 injection (Dose 5).",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"BW-50218 Dose 6","Single dose of BW-50218 injection (Dose 6).",[13],{"label":35,"type":36,"description":37,"interventionNames":38},"Saline Placebo","PLACEBO_COMPARATOR","Single dose of Saline Placebo",[39],"Drug: Saline (0.9% NaCl)",[41,47],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"DRUG","BW-50218 Injection","Solution for injection",[9,15,19,23,27,31],null,{"type":42,"name":48,"description":44,"armGroupLabels":49,"otherNames":46},"Saline (0.9% NaCl)",[35],[51],{"name":52,"affiliation":5,"role":53},"Yuqiong Li, MD","STUDY_DIRECTOR",[55],{"name":56,"role":57,"phone":58,"phoneExt":46,"email":59},"Zhi Hua","CONTACT","+86 185 1618 7545","zhi.hua@argobiopharma.com",[61,80],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"CMAX Clinical Research Pty Ltd","RECRUITING","Adelaide","South Australia","5000","Australia","AU",{"type":70,"coordinates":71},"Point",[72,73],138.59863,-34.92866,{"lat":73,"lon":72},[76],{"name":77,"role":57,"phone":78,"phoneExt":46,"email":79},"Sarada Radha","+61 8 7088 7900","Sarada.Radha@cmax.com.au",{"facility":81,"status":63,"city":82,"state":83,"zip":84,"country":67,"countryCode":68,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Linear Early Fhase Limited","Nedlands","Western Australia","6009",{"type":70,"coordinates":86},[87,88],115.8073,-31.98184,{"lat":88,"lon":87},[91],{"name":92,"role":57,"phone":93,"phoneExt":46,"email":94},"Jasmine Cahill Loring","+61 8 6382 5100","jloring@linear.org.au",{"type":96,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100623810","phase-1-study-of-bw-50218-in-healthy-participants-100623810",false,"NCT07401472","Study of BW-50218 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants","Inclusion Criteria:\n\n* Capable of providing written informed consent and complying with all study procedures for the duration of the study.\n* Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.\n* Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.\n* Male participants with partners of childbearing potential must agree to use effective contraception.\n\nExclusion Criteria:\n\n* Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.\n* Recent hospitalization or a significant acute medical event.\n* History of cancer or any long-term medical condition that the study doctor considers clinically relevant.\n* Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.\n* Positive test for hepatitis B, hepatitis C, or HIV.",true,"ALL","18 Years","65 Years",{"count":109,"type":110},60,"ESTIMATED","INTERVENTIONAL",[113],"PHASE1","Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants",[116],"Healthy Participants Study","2026-06-23",{"date":119,"type":120},"2026-06-24","ACTUAL",{"date":122,"type":120},"2026-03-12",{"date":124,"type":110},"2027-06-30",{"name":5,"class":6},2]